VetMedGuide

Vet Med Guide

Pharmaceuticals2026-05-14 · 12 min read

Senvelgo for Cats: Oral Diabetes Therapy, Ketone Risk, and Owner Monitoring

Senvelgo (velagliflozin) for cats — an oral SGLT2 inhibitor for newly diagnosed feline diabetes. Patient selection, euglycemic DKA risk, ketone monitoring, and when insulin is safer.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

Senvelgo (velagliflozin oral solution) is an FDA-approved, once-daily liquid medication for improving glycemic control in cats with diabetes mellitus that have never been treated with insulin. It belongs to a class of drugs called SGLT2 inhibitors — the same class used in human type 2 diabetes management — and it works by a completely different mechanism than insulin. Instead of pushing glucose into cells, velagliflozin causes the kidneys to excrete excess glucose in the urine.

For the right cat — a newly diagnosed, otherwise healthy diabetic with no history of insulin use — Senvelgo can eliminate the need for twice-daily injections and reduce the monitoring burden. But the label carries a boxed warning for a reason: cats that are not appropriate candidates can develop diabetic ketoacidosis (DKA), including a dangerous variant called euglycemic DKA where blood glucose appears normal despite life-threatening acidosis.

This article explains how velagliflozin works, which cats are candidates, what the monitoring protocol looks like, and what happens when things go wrong.

Quick answer

Senvelgo is a once-daily oral liquid (15 mg/mL) that costs roughly $60–80/month (prices vary by pharmacy). It is dosed at 1 mg/kg once daily — approximately 0.067 mL per kg of body weight. It can be given directly into the mouth or with a small amount of food.

In the SENSATION trial, blood glucose improved in most cats within the first week. By day 7, polyuria and polydipsia had improved in over 50% of treated cats. Fructosamine concentrations were routinely within the reference range after 8 weeks. Peripheral neuropathy improved in more than 75% of affected cats treated with velagliflozin.

The boxed warning: do not use in cats previously treated with insulin, cats currently receiving insulin, or cats suspected of having insulin-dependent diabetes. Switching an insulin-treated cat to Senvelgo is associated with an increased risk of DKA, euglycemic DKA, and death.

How SGLT2 inhibitors work in cats

Sodium-glucose cotransporter 2 (SGLT2) is a protein in the proximal tubule of the kidney that reabsorbs glucose from the urine back into the blood. In a healthy cat, virtually all filtered glucose is reabsorbed — none appears in the urine under normal conditions.

Velagliflozin blocks this transporter. Glucose that would have been reabsorbed is instead excreted in the urine. This lowers blood glucose through an insulin-independent mechanism. For cats that still produce enough of their own insulin to prevent ketone formation but cannot control blood glucose on their own, this can be effective monotherapy.

The key distinction: Senvelgo is not insulin. It does not replace insulin. It does not directly stop ketogenesis. A cat that lacks sufficient endogenous insulin production will continue to produce ketones even while blood glucose appears controlled — which is the mechanism behind euglycemic DKA.

Which cats are candidates — and which are not

Good candidates

The label describes the ideal patient as "otherwise healthy cats with diabetes mellitus not previously treated with insulin." The 2026 AAHA Diabetes Management Guidelines for Cats and the iCatCare 2025 consensus guidelines add clinical detail:

  • Newly diagnosed diabetic cat
  • Eating, drinking, and interactive — what the literature calls a "happy diabetic"
  • No vomiting, diarrhea, dehydration, lethargy, or cachexia
  • No ketonuria or ketonemia at diagnosis
  • No history of insulin treatment
  • No clinical signs suggesting concurrent disease that would complicate management (e.g., uncontrolled hyperthyroidism, pancreatitis, acromegaly)

Not candidates (contraindicated or high risk)

  • Any cat previously treated with insulin — the label contraindicates this explicitly. In the SENSATION study, insulin-treated diabetic cats had a ketonuria/DKA rate of 31.6%, compared to 10.7% in newly diagnosed cats. Previous insulin therapy increased the relative risk nearly threefold.
  • Cats with ketonuria or ketonemia at diagnosis — this suggests the cat may already have insufficient endogenous insulin production, or may have concurrent disease (pancreatitis, hepatic lipidosis).
  • Cats that are anorexic, lethargic, dehydrated, or vomiting — these are clinical signs that may indicate concurrent illness or developing DKA.
  • Cats with known pancreatitis — elevated fPL, imaging evidence, or clinical suspicion.

Gray areas requiring clinical judgment

  • Cats with concurrent but controlled hyperthyroidism or acromegaly — evidence is limited. The iCatCare 2025 guidelines suggest these cats can be considered for SGLT2 inhibitor therapy only with informed owner consent and close monitoring, acknowledging that data are sparse.
  • Cats with mild, transient ketonuria that resolves with initial supportive care — some clinicians will start SGLT2 inhibitor therapy after ketones clear, with enhanced monitoring.

The SENSATION trial evidence

The SENSATION study (Behrend et al., JAVMA 2024) was the pivotal trial. Key findings:

  • 252 cats total (214 newly diagnosed diabetic cats and 38 previously insulin-treated diabetic cats) received velagliflozin once daily.
  • In newly diagnosed cats, 88.4% were classified as treatment successes by day 30 (defined as improvement in at least one blood glucose variable and at least one clinical sign).
  • Blood glucose concentrations significantly decreased by day 7.
  • Polyuria and polydipsia improved in >50% of cats within the first week.
  • Overall rate of ketonuria or DKA was approximately 13%, with most cases occurring in the first 7 days.
  • No clinical hypoglycemia episodes — a major advantage over insulin therapy.

A separate trial (Niessen et al., JVIM 2024) compared velagliflozin directly to twice-daily insulin injections (Caninsulin). Mortality rates were similar between groups (7% velagliflozin vs. 8% Caninsulin), and velagliflozin achieved glycemic control without the hypoglycemia risk inherent to insulin therapy.

Dosing and administration

  • Dose: 1 mg/kg (approximately 0.067 mL/kg) once daily.
  • Formulation: 15 mg/mL oral liquid with a dosing syringe.
  • Administration: directly into the mouth or with a small amount of food.
  • Storage: room temperature, out of reach of other animals — accidental overdose in dogs or other pets is a documented risk.

There is no dose titration protocol in the label. The dose is the dose. If the cat does not respond, the drug should be discontinued and insulin started.

The monitoring protocol — this is not optional

The 2026 AAHA guidelines, the iCatCare 2025 consensus, and the Boehringer Ingelheim management guide all converge on a structured monitoring protocol. The highest-risk period is the first 14 days.

Before starting

  • Full diagnostic workup: blood glucose, fructosamine, serum chemistry, CBC, urinalysis, urine culture, urine ketones, blood beta-hydroxybutyrate (BHB) if available, fPL, total T4.
  • Rule out ketonuria, ketonemia, and pancreatitis.
  • Confirm the cat is eating well, not dehydrated, and clinically stable.

Days 1–14 (initial monitoring)

This is when most DKA/eDKA cases occur. The EMA's post-marketing review found that most serious events happened between days 0–4.

When What to check Who
Days 2–3 Urine ketones or blood BHB Owner at home (urine dipstick) or vet clinic
Day 7 Physical exam, urine ketones or blood BHB, weight, appetite assessment Veterinary clinic
Day 14 Physical exam, urine ketones or blood BHB, weight, clinical assessment Veterinary clinic
Continuous Appetite, attitude, water intake, urine output Owner at home

If ketones are detected at any point: stop Senvelgo immediately and start insulin. Do not wait to see if ketones clear on their own.

Day 28 and ongoing

When What to check
Day 28 Fructosamine, blood glucose, serum chemistry, urine ketones, weight, fPL, triglycerides, cholesterol
Every 3–6 months Fructosamine, serum chemistry, urine ketones, weight, clinical assessment

If fructosamine has not significantly improved by 4 weeks and the cat remains hyperglycemic with clinical signs of diabetes, discontinue Senvelgo and transition to insulin.

What the owner needs to do at home

Owners must be willing and able to:

  1. Check urine ketones every 1–3 days for the first 2 weeks using urine dipstick strips. This involves placing a strip in the cat's litter box (with non-absorbent litter or plastic wrap technique) or catching a urine sample.
  2. Monitor appetite, attitude, and water intake daily.
  3. Recognize the signs of DKA: sudden loss of appetite, lethargy, vomiting, dehydration, or weight loss — and seek immediate veterinary care if any of these occur.
  4. Understand that DKA can occur with normal blood glucose (euglycemic DKA), so blood glucose alone is not a reliable indicator that the cat is safe.

If an owner cannot commit to ketone monitoring in the first two weeks, Senvelgo is not an appropriate choice. Insulin therapy has a longer track record and does not carry the euglycemic DKA risk, though it requires injections and has its own hypoglycemia risk.

Euglycemic DKA — the specific risk of SGLT2 inhibitors

Euglycemic DKA (eDKA) is a life-threatening complication that is particular to SGLT2 inhibitor therapy. It occurs when the cat is producing enough endogenous insulin to keep blood glucose relatively normal but not enough to suppress ketogenesis in the liver. The result is metabolic acidosis with ketosis — a medical emergency — but with blood glucose that does not look alarming.

This makes eDKA harder to recognize than classic DKA. A cat that stops eating and becomes lethargic on Senvelgo might have "normal" blood glucose, leading the owner or clinician to think the diabetes is controlled. Meanwhile, the cat is acidotic and ketotic.

The diagnostic criterion: detect ketones (urine or blood) in a cat showing clinical signs of illness, regardless of blood glucose level. If ketones are present, treat for DKA and transition to insulin.

Switching to insulin if Senvelgo fails

If a cat does not respond (blood glucose remains above 250 mg/dL) or develops ketones:

  • Stop Senvelgo immediately.
  • In hyperglycemic cats, start insulin the following day.
  • In cats that are not hyperglycemic, withhold insulin until hyperglycemia develops (it may take several days for the SGLT2 inhibitor effect to wear off and glucose to rise).

The transition should not be gradual — stop the SGLT2 inhibitor and start insulin. The label and AAHA guidelines both emphasize this.

Comparison with Bexacat (bexagliflozin)

Bexacat (bexagliflozin) is the other FDA-approved SGLT2 inhibitor for feline diabetes, manufactured by Elanco. Key differences:

Feature Senvelgo (velagliflozin) Bexacat (bexagliflozin)
Formulation Oral liquid (15 mg/mL) Oral tablet
Dosing 1 mg/kg once daily 15 mg per cat once daily (cats > 3 kg)
Manufacturer Boehringer Ingelheim Elanco
BHB threshold for stopping Per label: do not start if ketonuria present; stop if ketones detected during treatment Per label: do not start if blood BHB >3.6 mmol/L, or if BHB >2.4 mmol/L with history of acidosis or renal compromise

Both carry the same boxed warning about DKA risk in insulin-treated cats. Both require the same structured ketone monitoring. The liquid formulation of Senvelgo may be easier for some owners than pilling a cat, while Bexacat's fixed tablet dose is simpler to administer for cats in the right weight range.

Side effects beyond DKA

From the SENSATION study and post-marketing data:

  • Ketonuria/DKA: approximately 14% overall in newly diagnosed cats; higher in previously insulin-treated cats
  • Gastrointestinal signs: occasional vomiting, diarrhea — typically mild and self-limiting
  • Urinary tract infections: SGLT2 inhibitors increase glucose in the urine, creating a favorable environment for bacterial growth. Monitor for clinical signs and culture urine if indicated.
  • Elevated triglycerides or cholesterol: may indicate declining glycemic control or pancreatitis. Prompt further evaluation.

The risk of clinical hypoglycemia is minimal because the mechanism is glucose excretion, not insulin-mediated glucose uptake. This is a genuine advantage over insulin therapy.

Practical decisions: what to ask your veterinarian

  • Is my cat a candidate for an SGLT2 inhibitor, or should we start with insulin? The answer depends on whether your cat has ever been on insulin, whether ketones are present, and whether your cat is clinically stable enough to tolerate an oral medication that requires close initial monitoring.
  • Can I commit to urine ketone monitoring for two weeks? If not, insulin may be the safer route despite the injection burden.
  • What signs should make me seek emergency care? Get a specific list: loss of appetite, lethargy, vomiting, and any behavioral change in the first two weeks on Senvelgo warrant an immediate ketone check and veterinary visit.
  • What is the plan if Senvelgo does not work? Have the transition-to-insulin plan established before starting. If your cat develops ketones or does not respond, you need to know what insulin will be used and how to start it.

Sources

Topics
Endocrinology
Related Articles